Shelton Capital Management Cuts Stock Holdings in DaVita Inc. (NYSE:DVA)

Shelton Capital Management cut its holdings in DaVita Inc. (NYSE:DVA) by 19.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,818 shares of the company’s stock after selling 14,900 shares during the quarter. Shelton Capital Management’s holdings in DaVita were worth $9,245,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. MML Investors Services LLC grew its holdings in DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after purchasing an additional 68 shares during the period. Exchange Traded Concepts LLC lifted its position in shares of DaVita by 8.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock valued at $133,000 after buying an additional 68 shares in the last quarter. Impact Partnership Wealth LLC grew its stake in shares of DaVita by 3.7% during the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock valued at $290,000 after acquiring an additional 70 shares during the period. Contravisory Investment Management Inc. increased its holdings in DaVita by 1.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after acquiring an additional 73 shares in the last quarter. Finally, Nilsine Partners LLC raised its stake in DaVita by 0.8% during the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock worth $1,669,000 after acquiring an additional 92 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Price Performance

NYSE:DVA opened at $146.59 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The business’s 50-day moving average is $155.17 and its 200 day moving average is $157.07. The company has a market capitalization of $11.73 billion, a P/E ratio of 13.65, a P/E/G ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DVA. Barclays increased their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. StockNews.com cut DaVita from a “buy” rating to a “hold” rating in a report on Wednesday, April 2nd. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.